November 5, 2010 – (BRONX, NY) – Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.
Insights into how normal body cells support tumor growth have led the way to a new wave of research and the development of therapeutics specifically targeting the support cells in the body that can aid in tumor development. Dr. Pollard's research has found that when macrophages are removed from the tumor microenvironment, the risk of cancer progressing to malignancy is reduced and its spread from the primary tumor site to distant sites lessens.
"I think that one of the major components of the therapeutic arsenal as we go forward will be to combine chemo-therapeutic drugs with drugs that target macrophages so that they can no longer support the tumor's ability to be malignant," said Dr. Pollard. "Further it gives another opportunity for therapy by using vaccination against tumor antigens combined with altering macrophages from tumor promoting to tumor rejecting. It gives us another prong in the attack on cancer."
Dr. Pollard is deputy director of the Albert Einstein Cancer Center, director of the Center for Study of Reproductive Biology and Women's Health and the Louis Goldstein Swan Chair in Women's Cancer Research at Einstein. He is also professor in the departments of developmental and molecular biology and obstetrics & gynecology and women's health at Einstein and Montefiore Medical Center.
This award from the American Cancer Society, the nation's leading voluntary health organization and largest non-governmental investor in cancer research, represents the Society's highest honor in recognition of outstanding contributions to fighting cancer.
The award was presented at the American Cancer Society's annual meeting in Atlanta, GA. In addition to Dr. Pollard, the ACS recognized Joseph Fraumeni, M.D., M.Sc., for Cancer Control, and Patricia Ganz, M.D., for Clinical Research.
This is the second ACS Medal of Honor awarded to a researcher at the Albert Einstein Cancer Center. Susan Band Horwitz, Ph.D., received the Medal of Honor in 2008 for Clinical Research.
About Albert Einstein College of Medicine of Yeshiva University
Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. During the 2009-2010 academic year, Einstein is home to 722 M.D. students, 243 Ph.D.students, 128 students in the combined M.D./Ph.D. program, and approximately 350 postdoctoral research fellows. The College of Medicine has 2,775 fulltime faculty members located on the main campus and at its clinical affiliates. In 2009, Einstein received more than $155 million in support from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five medical centers in the Bronx, Manhattan and Long Island - which includes Montefiore Medical Center, The University Hospital and Academic Medical Center for Einstein - the College of Medicine runs one of the largest post-graduate medical training programs in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training. For more information, please visit www.einstein.yu.edu